Rosacea News and Research

Latest Rosacea News and Research

CDA launches Acne And Rosacea Awareness Campaigns

The temperature drop outside is leaving many Canadians red in the face but dermatologists say the culprit could be acne or rosacea. The Canadian Dermatology Association (CDA) is launching Acne and Rosacea Awareness Campaigns to give sufferers the advice they need to cope with these diseases.

8 Dec 2009

New study reveals certain prescription drugs can be harmful to fetus

More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Universit- de Montr-al investigation published in the British Journal of Obstetrics and Gynaecology

18 Nov 2009

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

11 Nov 2009

Tips for treating age-related dermatologic concerns

Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.

11 Nov 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Premier Plastic Surgery of Kansas City, serving residents of Kansas City and beyond for 22 years, has redesigned its extensive website to include a separate section on Cosmetic Surgery for Males, a new Skin Care Centre, and a Plastic Surgery Blog that features breaking news on emerging research, techniques and products.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009

New consumer At-Home Skin Typing and Analysis Kit unveiled

Reveal Sciences, LLC, a cosmetics and aesthetics innovation company pioneering breakthrough skin care diagnostics, has announced the launch of the new consumer At-Home Skin Typing and Analysis Kit.

5 Oct 2009

Impax Laboratories challenges Galderma Laboratories' patents

Impax Laboratories, Inc. confirms that it has initiated a challenge of the patents listed by Galderma Laboratories, L.P. in connection with its ORACEA® (doxycycline) delayed-release capsules, 40 mg.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

11 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Mylan confirms four first-to-file challenges

Mylan Inc. has announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).

29 Mar 2009

Galderma to acquire CollaGenex Pharmaceuticals

Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex.

27 Feb 2008

FDA warns Melanocorp for illegal sale of Melanotan II

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to Brian Manookian, owner of Melanocorp, Inc. in Hendersonville, Tenn. for the illegal sale and marketing of the product Melanotan II, which is not FDA-approved, on Melanocorp's Web site.

5 Sep 2007

What causes rosacea?

Doctors can describe the symptoms of rosacea, a common inflammatory skin disease that causes facial redness and affects nearly 14 million Americans.

6 Aug 2007

Rosacea the result of a trifecta of unfortunate factors

Rosacea is a common inflammatory skin disease that causes facial redness which affects as many as 14 million Americans.

6 Aug 2007

New oral acne medications work best

While laser and light-based therapies continue to make their mark on many dermatologic procedures, some dermatologists believe the tried-and-true oral medications for treating moderate to severe acne offer patients the best long-term treatment outcomes.

2 Aug 2007